+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
P

Actively Recruiting

Researchers are evaluating a hand-held vibration therapy device as a potential way to reduce the severity of chemotherapy-induced peripheral neuropathy CIPN in the hands. This pilot study aims to assess the safety and feasibility of using daily 3-minute vibration therapy to improve symptoms and quality of life for patients who have completed chemotherapy and continue to experience CIPN. The study hopes to provide early data to support future clinical trials exploring this therapy option. Participants will use a hand-held vibrating device for 3 minutes on each hand every day over a 4-week period. This intervention is being studied for its ability to lessen CIPN symptoms and improve patient quality of life. The study includes only one treatment group, and the primary focus is on testing whether patients can adhere to the therapy and tolerate it safely. During the study, participants will be regularly assessed using questionnaires that measure CIPN severity and related quality of life at baseline and weekly throughout the 4 weeks, with additional follow-ups up to 8 weeks. Researchers will track recruitment success, therapy compliance, and patient acceptability of the intervention. Safety and symptom changes will be monitored to evaluate the therapys effects and feasibility for future research. The total study duration spans several years, with individual participation lasting at least 4 weeks plus follow-up.

Age: 18Years +All GendersPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
V

Actively Recruiting

Researchers are studying the effects of exercise in adults with indolent metastatic breast cancer who have not had disease progression in the past 12 months and are not receiving cytotoxic chemotherapy. The study aims to see if a 16-week virtual, supervised exercise program combining aerobic and resistance training can improve heart and lung fitness, physical function, muscle mass, and patient-reported quality of life measures. This trial is a randomized, two-arm study comparing exercise to usual care in this specific patient group. Participants are randomly assigned to either an exercise intervention or usual care. Those in the exercise group will work with a trainer three times a week for 16 weeks in virtual sessions lasting 60 minutes. Each session includes cardiovascular exercise, resistance training, and balance or stretching exercises, with intensity adjusted based on heart rate and perceived exertion. The usual care group receives standard care and educational handouts encouraging exercise but no structured program. Throughout the study, participants will undergo tests to measure cardiorespiratory fitness, physical performance, muscle and fat composition via CT scans, and physical activity tracking. Patient-reported outcomes like fatigue and quality of life will also be assessed at baseline, 8 weeks, and 16 weeks. Researchers will monitor adherence to the exercise program and evaluate changes in physical and patient-reported measures to understand the impact of the intervention over the 16-week period.

Age: 18Years +All GendersPhase Not Applicable
6 locations
R

Actively Recruiting

Researchers are comparing durvalumab immunotherapy to the usual post-surgery observation approach for people with early-stage non-small cell lung cancer who have no remaining cancer cells after standard treatment. This phase III trial focuses on patients with stage II to IIIB disease who achieved a complete response following neoadjuvant chemo-immunotherapy. The study aims to find out whether durvalumab can help patients live longer and prevent cancer from coming back compared to just monitoring after surgery. Participants are randomly assigned to one of two groups. One group receives durvalumab intravenously once every 28 days for up to 12 cycles, provided there is no disease progression or unacceptable side effects. The other group undergoes active surveillance without additional treatment for 12 months. During the trial, all participants have regular CT scans and blood samples taken. After treatment or surveillance, patients are followed annually for up to 10 years. Throughout the study, participants complete questionnaires assessing quality of life and symptoms. Researchers monitor disease-free survival, overall survival, and adverse events up to 10 years after randomization. The trial also collects specimens and images for future research. Participants have regular visits for scans, blood tests, and assessments to evaluate the safety and effects of durvalumab compared to observation.

Age: 18Years +All GendersPhase 3
284 locations
C

Actively Recruiting

Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.

Age: 18Years +All GendersPhase 3
846 locations
E

Actively Recruiting

This research aims to explore the feasibility of adding pre-rehabilitation pelvic health physical therapy to the standard radiation therapy plan for female patients diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer who are candidates for curative pelvic radiation with external beam. The study focuses on addressing common post-treatment side effects like pelvic pain and painful intercourse, which significantly affect quality of life. It also seeks to understand the challenges and benefits of implementing a coordinated pelvic health service alongside radiation oncology. Participants will receive education on using a vaginal dilator during their radiation treatment as part of a multidisciplinary approach involving pelvic health physical therapy. The study includes assessments such as physical therapy evaluations with pelvic floor muscle examination, and the use of questionnaires to monitor pain, sexual function, and adherence to vaginal dilator use. The vaginal dilator is a device designed to help maintain vaginal canal openness and stretch pelvic floor muscles, aiming to reduce pelvic pain and dyspareunia. During the study, participants will complete various questionnaires including the Female Sexual Function Index and Visual Pain Rating Scale at multiple time points after radiation therapy. Adherence to dilator use will be tracked through specific questionnaires. The research team will evaluate the feasibility of implementing this pre-rehabilitation program from baseline through up to four months post radiation. Overall participation may last several months, with ongoing assessments to monitor pain, sexual function, and treatment adherence, helping researchers understand the potential clinical value of this approach.

Age: 18Years +FEMALEPhase Not Applicable
3 locations
V

Actively Recruiting

Researchers are evaluating a survival prediction tool developed by Lee et al. for patients with metastatic cancer who are referred to radiation oncology for palliative treatments. This phase II clinical trial aims to validate the tools ability to predict 30-day survival by assigning a score based on objective data including laboratory values, emergency room visits, and primary cancer origin. The study categorizes patients into low-, intermediate-, and high-risk groups based on their scores. The prediction tool calculates a score from 0 to 20, where higher scores indicate a worse survival prognosis. Participants receive a score at enrollment, and their survival chances are monitored over 30, 90, and 365 days. The tool uses lab values such as white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, along with emergency room attendance and cancer type to generate the score. Participants survival and quality of life will be tracked at regular intervals using the FACIT-Pal-14 questionnaire. Researchers will assess survival rates at 30, 90, and 365 days within each risk group and evaluate patient-reported quality of life. Follow-up can be conducted virtually or by phone, and the total study duration extends up to one year after enrollment to monitor these outcomes.

Age: 18Years +All Genders
3 locations

1-10 of 17

1